ANI Pharmaceuticals, Inc. (ANIP) Stock

Understand ANI Pharmaceuticals, Inc.: how it makes money

ANI Pharmaceuticals develops, manufactures, and markets prescription pharmaceuticals in the United States and Canada, earning revenue from sales of branded and generic drugs (including rare disease and generics) and also from contract development and manufacturing for other companies.

Profit is driven by the product mix, where branded and rare disease revenues and generics revenues flow from ANI's in-house pharmaceutical manufacturing and marketing channels (including retail pharmacy chains, wholesalers, and distributors).

Business quality (Solid): Clear business model and product categories, but the provided segment breakdown is limited, and the key operating metrics available are segment or product revenue lines rather than broader operational drivers.

Valuation: At 21× earnings, ANIP trades 24% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

• Revenue mix includes both rare disease and brands, and generics: The company reports segment revenue for Rare Disease and Brand Revenues and Generics Revenue, which can help diversify demand across different pharmaceutical categories.
• Manufacturing and marketing are both core: ANI develops, manufactures, and markets branded and generic prescription pharmaceuticals, which supports internal control over product supply for its marketed portfolio.
• Operational profitability is positive in the latest period provided: Operating margin is 16.4% for the period ending 2026-03-31.

Bear case

• Concentration risk in specific product lines: The provided metric candidates highlight particular gel products such as Cortofin Gel and Cortrophin Gel, which can imply reliance on specific therapies within rare disease and brand revenues.
• Regulatory and product risk is inherently higher for certain categories: ANI focuses on producing controlled substances and potent products, which can increase regulatory and compliance sensitivity for operations and product continuity.
• Generics category can face pricing pressure: Generics Revenue is a named revenue line in the available operating metrics, and generics businesses are typically more exposed to competitive pricing than branded therapies.

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

• Arrowhead Pharmaceuticals, Inc. (ARWR)
• Ionis Pharmaceuticals, Inc. (IONS)
• Madrigal Pharmaceuticals, Inc. (MDGL)
• Collegium Pharmaceutical, Inc. (COLL)
• Corcept Therapeutics Incorporated (CORT)
• Emergent BioSolutions Inc. (EBS)
• ACADIA Pharmaceuticals Inc. (ACAD)
• Amphastar Pharmaceuticals, Inc. (AMPH)